Kathleen Murphy

Researcher

UAMS

Also affiliated: Boston University (2017); Texas Tech University (1997–2000); Novartis (Switzerland) (2024); Fox Chase Cancer Center (2017–2021); Arkansas Children's Hospital (2024); Memorial Hermann (2016); Texas Medical Center (1996); Henry Ford Health System (1996); University of Illinois Urbana-Champaign (2019); Genetic Alliance (2022); RTI International (2022); Baylor College of Medicine (1996–2007); Washington University in St. Louis (2022); Hospital of the University of Pennsylvania (2018–2020); Veterans Health Administration (1996); Harris Health System (2000–2014); Dana-Farber Cancer Institute (2017); Novartis (United States) (2022–2024); Texas Children's Hospital (2007); Stony Brook Children's Hospital (2018); Texas Research Institute (2016); Hospice UK (1997); Milwaukee Public Schools (2005); Tris Pharma (United States) (2024); All Saints Hospital (1976); University of Pennsylvania (2018); The University of Texas at Austin (2010–2016); The University of Texas Health Science Center at Houston (2011–2016); Texas Tech University Health Sciences Center (1997–2000)

Faculty Researcher

12 h-index 41 pubs 1,086 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Kathleen Murphy's research investigates the pathogenesis of oncogenic gammaherpesviruses, including mechanisms of viral-driven genomic instability in B cells and the functions of the KSHV LANA protein in viral pathogenesis and immune evasion. She has received federal funding from the National Institutes of Health (NIH) to support this work, serving as Principal Investigator (PI) on grants totaling over $845,000 for projects defining gammaherpesvirus mechanisms and KSHV LANA functions. Additionally, she is a Co-PI on an NIH-funded project examining how periodontal bacteria enhance oral KSHV pathogenesis and Kaposi's Sarcoma development in HIV-positive patients, receiving over $324,000.

Murphy's scholarly output includes 41 publications and over 1,080 citations, with an h-index of 12. Her recent publications explore diverse areas, including a national registry for kidney disease patients, a palliative care intervention for head and neck cancer, growth trajectories following early antibiotic exposure, and treatment patterns for complement 3 glomerulopathy (C3G). She also contributes to research on respiratory distress in preterm neonates and characteristics of C3G patients in multi-center assessments.

Her work is supported by collaborations with colleagues at the University of Arkansas for Medical Sciences, including Z. Ghazala, David N. Matlock, Laura Gonzalez‐Krellwitz, and Adam Ross, with whom she has co-authored publications. Murphy maintains an active lab website to disseminate her research.